March 14, 2018 / 11:10 AM / 3 months ago

BRIEF-UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3

March 14 (Reuters) - Uniqure Nv:

* UNIQURE ANNOUNCES 2017 FINANCIAL RESULTS AND RECENT COMPANY PROGRESS

* UNIQURE NV - ‍ON TRACK TO BEGIN PIVOTAL STUDY OF AMT-061 IN HEMOPHILIA B IN Q3 2018​

* UNIQURE NV - ‍EXPECTS IND SUBMISSION FOR AMT-130 IN HUNTINGTON’S DISEASE IN SECOND HALF OF 2018​

* UNIQURE NV - ‍$159 MILLION OF CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below